Hormonal
Tirzepatide facilitates significant weight loss and improves lipid profiles in individuals with spinal cord injury (SCI) who are refractory to standard dietary and exercise interventions.
If you have a spinal cord injury and have tried strict diet and exercise without success, ask your doctor about tirzepatide. It is a weekly injection that helped this patient lose 33 pounds and improve his cholesterol, even when standard lifestyle changes failed. Be aware that GI side effects are possible, though this patient tolerated them well.
After 3 months of treatment, he lost 31 pounds and saw improvements in his lipid profile... Tirzepatide may be an effective adjunct therapy to lifestyle interventions to help prevent CMD in those with SCI.
Why this rating
This is a single case report (n=1), which provides low generalizability despite clear observed effects in the subject.
Source
Treatment of obesity in spinal cord injury with tirzepatide: a case report
Michael Juszczak et al. · Spinal Cord Series and Cases · 2025
DOI 10.1038/s41394-025-00699-w
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →